Rosuvastatin and Ezetimibe loaded PLGA: an investigation approach for the treatment of hyperlipidemia induced by Triton in male albino rats

Abstract

This study aimed to develop and optimize the anti-hyperlipidemic effect of Ezetimibe (EZE) and Rosuvastatin (RSV) combination using poly (lactic-co-glycolic acid) nanoparticles (NPs). To achieve this, in vivo Triton induced hyperlipidemia rats were used to evaluate the antihyperlipidemic activity of the marketed products in comparison with their NPs. Results revealed that after 24 hours, Triton treated animals showed altered lipid profiles including significantly (P<0.05) high cholesterol, triglycerides, LDL-C and Non-HDL-C and low HDL-C. They also exhibited an increase in the activities of ALT and AST enzymes, creatinine, urea, and blood urea nitrogen levels and a decline in the total proteins and albumin levels indicating liver and kidney injuries. Triton also altered the glycemic control as evidenced by the increase in glucose and insulin growth factor. Administration of orally EZE+RSV and their loaded NPs significantly (P<0.05) attenuated the lipids alters after 15 days of treatment. This attenuation was continued up to 30 days in many evaluated parameters. They also were effective in partial preventing liver and kidney injuries and the glycemic controls. The effects of NPs were more pronounced that the marketed forms. In conclusion, and based on our findings, the efficiency and convenience of anti-hyperlipidemic activity of EZE+RSV nanoparticles were well demonstrated.